We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
That’s great thanks
I'm not sure that 30 day rule applies on AIM, however in this case she wouldn't necessarily be an insider having subscribed for shares prior to joining the company. She also paid well above market rate which is unusual, perhaps this was to emphasise it was an arms length transaction.
My expectation is we'll get a big RNS between now and the end of the year, which will either be an update on the AZN collaboration (the 1 year anniversary of it's announcement will be in December) or the announcement of the new collaboration with Novartis. Of course something left field could arrive, but the above two would be favourites IMO.
Great post shearclass - so when do we think this news is likely to drop? Am I right in thinking that no significant news can be announced within 30days of directors deals?therefore 30 days from the newly appointed directors purchase would be a rough timescale? Heard this mentioned in previous share I’ve been in and it was pretty accurate in that instance - cheers
Yes I thought that was a ridiculous response from JAdam, it is a complex company, hence why it's under the radar.
In simple terms DeepMatter were formally called Cronin Group, having bought Cronin 3D for £5m back in 2015. DeepMatter own the trademark to the Chemputer, but the CNBC article posted over the weekend references work done by Lee Cronin's new entity, Chemify. So DeepMatter aren't linked directly to GSK at present, if they were there would have been an RNS!
However, DeepMatter do have ongoing collaborations / assessments underway with big pharma to assess DigitalGlassware, which is to my understanding the early Chemputer work done by Cronin which allows systematic recording, coding & sharing of chemistry data in the cloud. The Astra collaboration announced last December is the most significant to date, and a Novartis collaboration was mentioned in the July placing as being in the process of being finalised. News from either of these two will instantly double the share price I'd imagine.
My take away from the CNBC article would be that the new Chemputer work being undertake by Cronin flags his brilliance & adds renewed credibility to DeepMatter, increasing the likelihood of AZN / Novartis / other big pharma signing long terms deals for DigitalGlassware etc. You'd also have to think that if Lee Cronin wanted to capitalise on the new work done by Chemify there is half a chance that DMTR could acquire them in a similar way to their Cronin 3D acquisition.
An interesting company for sure, and one I'm happy to have in my portfolio at the current valuation. DeepVerge is certainly a comparable in that it's an AI focused life sciences company, post it's Modern Water merger it'll be valued at around £50m, which is almost 3 x DMTR. Additionally DeepVerge don't have relationships with AZN or big pharma, which makes the risk reward here even better IMO.
Ta for the response Adam.
Last I checked a forum was a medium for posting questions, ideas or thoughts.
Cheers for the advice but after much soul searching my response to yours would be yes and yes. What a feckin bell end!!!
Bit harsh that, forums are for debate, questions & reasearch. This company isn't exactly the most straight forward. He's probably asking the question to confirm his reasearch on a possible investment in the business
Cronin is a goat, helping the US and UK goverments during lock down, they are into everything........ Tick tock
Just watched the video on YouTube of Lee Cronin discussing the Chemputer. I get he has a stake in DMTR but what is the link between DMTR and the Chemputer?